Rundu swings to profit as new heart drugs win approvals
New hypertension drug approvals widen product line Rundu won Chinese approval for azilsartan tablets and, separately, marketing approval for amlodipine besylate, the key ingredient in a common blood-pressure medicine. Both add to its heart and stroke product range, supporting future sales and its ingredient-to-finished-pill chain.
These regulatory approvals are genuinely new and expand the products the company can sell.
Innovative heart-imaging drug gets provincial support Rundu's first-in-class higenamine hydrochloride injection was picked for Guangdong's innovative drug catalog. That status brings provincial policy support for promoting and selling the product, which should help it reach more hospitals and patients over time.
This is a new regulatory win that could lift sales of a high-value innovative product.
Controlling shareholder still heavily pledged Controlling shareholder Li Xi released 2.15 million pledged shares, but 97.2% of his stake remains pledged. Heavy pledging can signal personal financial strain and, if shares fall, risks forced selling that would weigh on the stock price.
This is the main counterweight to the good news and a real risk investors should weigh.